The Concept of CMR
Slides, videos and moreManaging CMR
Preventing Type 2 Diabetes
Targeting Abdominal Obesity
- 1Key Points (1 page)
- 2Targeting Abdominal Obesity to Manage the Metabolic Syndrome (1 page)
- 3Lifestyle Interventions (5 pages)
- 4Pharmacotherapy for the Prevention of Type 2 Diabetes (4 pages)
- 5References (1 page)
Lifestyle Interventions
3 of 12
Figure 1: 
Figure 1: Although each component of the metabolic syndrome can be targeted separately through pharmacotherapy, it is also possible to take a more global therapeutic approach to treating the metabolic syndrome and/or type 2 diabetes by focusing on reducing excess atherogenic/diabetogenic intra-abdominal adipose tissue, which is often present in patients with the clustering abnormalities of this syndrome. The causes of this preferential adipose tissue accumulation include an obesogenic and diabetogenic diet, a low level of physical activity leading to a positive energy balance, and genetic susceptibility. These causes should all be targeted to reduce the risk of developing the metabolic syndrome and type 2 diabetes (4). As depicted in Figure 1, abdominally obese individuals should be encouraged to increase their daily energy expenditure in order to decrease intra-abdominal adipose tissue and improve their plasma lipoprotein-lipid profile and indices of plasma glucose-insulin homeostasis. Typically, this loss of intra-abdominal adipose tissue reduces free fatty acid flux to the liver, which slows hepatic VLDL production, lowers plasma triglyceride and apolipoprotein B levels, and increases HDL cholesterol concentrations (5). It also changes the pattern of adipose tissue secretory products, causing interleukin-6 levels to fall and adiponectin concentrations to rise, which improves insulin sensitivity (6, 7). The end product of abdominal fat loss is a reduction in CRP levels.
3 of 12
